Table of Contents Author Guidelines Submit a Manuscript
Obstetrics and Gynecology International
Volume 2010 (2010), Article ID 486164, 5 pages
http://dx.doi.org/10.1155/2010/486164
Review Article

The LH/hCG Axis in Endometrial Cancer: A New Target in the Treatment of Recurrent or Metastatic Disease

1Department of Experimental Pathology and Oncology, Unversity of Florence, Viale GB Morgagni, 50, 50134 Firenze, Italy
2Department of Gynaecology, Perinatology and Human Reproduction, University of Florence, Viale GB Morgagni, 85, 50134 Firenze, Italy

Received 26 November 2009; Revised 26 May 2010; Accepted 16 June 2010

Academic Editor: Paul J. Hoskins

Copyright © 2010 A. Arcangeli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. A. Wingo, L. A. G. Ries, G. A. Giovino et al., “Annual report to the nation on the status of cancer, 1973–1996, with a special section on lung cancer and tobacco smoking,” Journal of the National Cancer Institute, vol. 91, no. 8, pp. 675–690, 1999. View at Google Scholar · View at Scopus
  2. F. Amant, P. Moerman, P. Neven, D. Timmerman, E. Van Limbergen, and I. Vergote, “Endometrial cancer,” Lancet, vol. 366, no. 9484, pp. 491–505, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. P. G. Rose, “Endometrial carcinoma,” New England Journal of Medicine, vol. 335, no. 9, pp. 640–649, 1996. View at Publisher · View at Google Scholar · View at Scopus
  4. S. F. Lax, “Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification,” Virchows Archiv, vol. 444, no. 3, pp. 213–223, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. H. B. Salvesen, O. E. Iversen, and L. A. Akslen, “Prognostic significance of angiogenesis and ki-67, p53, and p21 expression: a population-based endometrial carcinoma study,” Journal of Clinical Oncology, vol. 17, no. 5, pp. 1382–1390, 1999. View at Google Scholar · View at Scopus
  6. J. Lin, Z. M. Lei, S. Lojun, C. V. Rao, P. G. Satyaswaroop, and T. G. Day, “Increased expression of luteinizing hormone/human chorionic gonadotropin receptor gene in human endometrial carcinomas,” Journal of Clinical Endocrinology and Metabolism, vol. 79, no. 5, pp. 1483–1491, 1994. View at Publisher · View at Google Scholar · View at Scopus
  7. M. C. Pike, R. K. Peters, W. Cozen et al., “Estrogen-progestin replacement therapy and endometrial cancer,” Journal of the National Cancer Institute, vol. 89, no. 15, pp. 1110–1116, 1997. View at Google Scholar · View at Scopus
  8. L. Deligdisch and C. F. Holinka, “Endometrial carcinoma: two diseases?” Cancer Detection and Prevention, vol. 10, no. 3-4, pp. 237–246, 1987. View at Google Scholar · View at Scopus
  9. J. G. Pierce and T. F. Parsons, “Glycoprotein hormones: structure and function,” Annual Review of Biochemistry, vol. 50, pp. 465–495, 1981. View at Google Scholar · View at Scopus
  10. C. V. Rao and Z. M. Lei, “The past, present and future of nongonadal LH/hCG actions in reproductive biology and medicine,” Molecular and Cellular Endocrinology, vol. 269, no. 1-2, pp. 2–8, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. Entrez Gene, October 2009, http://www.ncbi.nlm.nih.gov/.
  12. “Ensembl genome browser,” October 2009, http://www.ensembl.org/index.html.
  13. “Atlas of Genetics and Cytogenetics in Oncology and Haematology,” October 2009, http://atlasgeneticsoncology.org/.
  14. R. E. Dickinson, A. J. Stewart, M. Myers, R. P. Millar, and W. C. Duncan, “Differential expression and functional characterization of luteinizing hormone receptor splice variants in human luteal cells: implications for luteolysis,” Endocrinology, vol. 150, no. 6, pp. 2873–2881, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. K. C. McFarland, R. Sprengel, H. S. Phillips et al., “Lutropin-choriogonadotropin receptor: an unusual member of the G protein-coupled receptor family,” Science, vol. 245, no. 4917, pp. 494–499, 1989. View at Google Scholar · View at Scopus
  16. M. Ascoli, F. Fanelli, and D. L. Segaloff, “The lutropin/choriogonadotropin receptor, a 2002 perspective,” Endocrine Reviews, vol. 23, no. 2, pp. 141–174, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Guo, I. H. Russo, M. H. Lareef, and J. Russo, “Effect of human chorionic gonadotropin in the gene expression profile of MCF-7 cells,” International Journal of Oncology, vol. 24, no. 2, pp. 399–407, 2004. View at Google Scholar · View at Scopus
  18. M. L. Dufau, “The luteinizing hormone receptor,” Annual Review of Physiology, vol. 60, pp. 461–496, 1998. View at Publisher · View at Google Scholar · View at Scopus
  19. L. M. Salvador, E. Maizels, D. B. Hales, E. Miyamoto, H. Yamamoto, and M. Hunzicker-Dunn, “Acute signaling by the LH receptor is independent of protein kinase C activation,” Endocrinology, vol. 143, no. 8, pp. 2986–2994, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Hirakawa, C. Galet, and M. Ascoli, “MA-10 cells transfected with the human lutropin/choriogonadotropin receptor (hLHR): a novel experimental paradigm to study the functional properties of the hLHR,” Endocrinology, vol. 143, no. 3, pp. 1026–1035, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Stepien and A. J. Ziecik, “Second messenger systems in the action of LH and oxytocin on porcine endometrial cells in vitro,” Theriogenology, vol. 57, no. 9, pp. 2217–2227, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Ryan, P. Glister, P. Lonergan, F. Martin, P. G. Knight, and A. C. Evans, “Functional significance of the signal transduction pathways Akt and Erk in ovarian follicles: in vitro and in vivo studies in cattle and sheep,” Journal of Ovarian Research, vol. 1, no. 1, article 2, 2008. View at Google Scholar
  23. S. S. C. Yen and R. B. Jaffe, Reproductive Endocrinology, W. B. Saunders, Philadelphia, Pa, USA, 3rd edition, 1991.
  24. E. Reshef, Z. M. Lei, C. V. Rao, D. D. Pridham, N. Chegini, and J. L. Luborsky, “The presence of gonadotropin receptors in nonpregnant human uterus, human placenta, fetal membranes, and decidua,” Journal of Clinical Endocrinology and Metabolism, vol. 70, no. 2, pp. 421–430, 1990. View at Google Scholar · View at Scopus
  25. S. Bhattacharya, J. Banerjee, S. Sen, and P. R. Manna, “Human chorionic gonadotropin binding sites in the human endometrium,” Acta Endocrinologica, vol. 129, no. 1, pp. 15–19, 1993. View at Google Scholar · View at Scopus
  26. S. W. Han, Z. M. Lei, and C. V. Rao, “Homologous down-regulation of luteinizing hormone/chorionic gonadotropin receptors by increasing the degradation of receptor transcripts in human uterine endometrial stromal cells,” Biology of Reproduction, vol. 57, no. 1, pp. 158–164, 1997. View at Publisher · View at Google Scholar · View at Scopus
  27. F. Raga, E. M. Casañ, J. S. Kruessel et al., “Quantitative gonadotropin-releasing hormone gene expression and immunohistochemical localization in human endometrium throughout the menstrual cycle,” Biology of Reproduction, vol. 59, no. 3, pp. 661–669, 1998. View at Google Scholar · View at Scopus
  28. M. Shemesh, “Actions of gonadotrophins on the uterus,” Reproduction, vol. 121, no. 6, pp. 835–842, 2001. View at Google Scholar · View at Scopus
  29. P.-J. Bonnamy, A. Benhaim, and P. Leymarie, “Human chorionic gonadotropin affects tissue levels of progesterone and cyclic adenosine 3',5'-monophosphate in the metestrus rat uterus in vitro,” Biology of Reproduction, vol. 40, no. 3, pp. 511–516, 1989. View at Google Scholar · View at Scopus
  30. S. W. Han, Z. M. Lei, and C. V. Rao, “Up-regulation of cyclooxygenase-2 gene expression by chorionic gonadotropin in mucosal cells from human fallopian tubes,” Endocrinology, vol. 137, no. 7, pp. 2929–2937, 1996. View at Publisher · View at Google Scholar · View at Scopus
  31. B. Gawronska, A. Stepien, and A. J. Ziecik, “Role of luteinizing hormone in control of oviduct function,” Reproduction in Domestic Animals, vol. 35, no. 3-4, pp. 129–133, 2000. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Lojun, S. Bao, Z. M. Lei, and C. V. Rao, “Presence of functional luteinizing hormone/chorionic gonadotropin (hCG) receptors in human breast cell lines: implications supporting the premise that hCG protects women against breast cancer,” Biology of Reproduction, vol. 57, no. 5, pp. 1202–1210, 1997. View at Publisher · View at Google Scholar · View at Scopus
  33. G. Hudelist, A. Huber, M. Knoefler et al., “β-HCG/LH receptor (β-HCG/LH-R) expression in eutopic endometrium and endometriotic implants: evidence for β-HCG sensitivity of endometriosis,” Reproductive Sciences, vol. 15, no. 6, pp. 543–551, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. Z. M. Lei, P. Toth, C. V. Rao, and D. Pridham, “Novel coexpression of human chorionic gonadotropin (hCG)/human luteinizing hormone receptors and their ligand hCG in human fallopian tubes,” Journal of Clinical Endocrinology and Metabolism, vol. 77, no. 3, pp. 863–872, 1993. View at Publisher · View at Google Scholar · View at Scopus
  35. Z. M. Lei, C. V. Rao, S. R. Lincoln, and D. M. Ackermann, “Increased expression of human chorionic gonadotropin/human luteinizing hormone receptors in adenomyosis,” Journal of Clinical Endocrinology and Metabolism, vol. 76, no. 3, pp. 763–768, 1993. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Davies, C. M. R. Bax, E. Chatzaki, T. Chard, and R. K. Iles, “Regulation of endometrial cancer cell growth by luteinizing hormone (LH) and follicle stimulating hormone (FSH),” British Journal of Cancer, vol. 83, no. 12, pp. 1730–1734, 2000. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Lin, Z. M. Lei, S. Lojun, C. V. Rao, P. G. Satyaswaroop, and T. G. Day, “Increased expression of luteinizing hormone/human chorionic gonadotropin receptor gene in human endometrial carcinomas,” Journal of Clinical Endocrinology and Metabolism, vol. 79, no. 5, pp. 1483–1491, 1994. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Mandai, I. Konishi, H. Kuroda et al., “Messenger ribonucleic acid expression of LH/hCG receptor gene in human ovarian carcinomas,” European Journal of Cancer Part A, vol. 33, no. 9, pp. 1501–1507, 1997. View at Publisher · View at Google Scholar · View at Scopus
  39. I. Noci, S. Pillozzi, E. Lastraioli et al., “hLH/hCG-receptor expression correlates with in vitro invasiveness in human primary endometrial cancer,” Gynecologic Oncology, vol. 111, no. 3, pp. 496–501, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Dabizzi, I. Noci, P. Borri et al., “Luteinizing hormone increases human endometrial cancer cells invasiveness through activation of protein kinase A,” Cancer Research, vol. 63, pp. 4281–4286, 2003. View at Google Scholar
  41. C. Lhommé, P. Vennin, N. Callet et al., “A multicenter phase II study with triptorelin (sustained-release LHRH agonist) in advanced or recurrent endometrial carcinoma: a French Anticancer Federation study,” Gynecologic Oncology, vol. 75, no. 2, pp. 187–193, 1999. View at Publisher · View at Google Scholar · View at Scopus
  42. A. R. Jeyarajah, C. J. Gallagher, P. R. Blake et al., “Long-term follow-up of gonadotrophin-releasing hormone analog treatment for recurrent endometrial cancer,” Gynecologic Oncology, vol. 63, no. 1, pp. 47–52, 1996. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Covens, G. Thomas, P. Shaw et al., “A phase II study of Leuprolide in advanced/recurrent endometrial cancer,” Gynecologic Oncology, vol. 64, no. 1, pp. 126–129, 1997. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Markman, A. Kennedy, K. Webster et al., “Leuprolide in the treatment of endometrial cancer (multiple letters),” Gynecologic Oncology, vol. 66, no. 3, p. 542, 1997. View at Google Scholar · View at Scopus
  45. R. F. Asbury, V. L. Brunetto, R. B. Lee, G. Reid, and T. F. Rocereto, “Goserelin acetate as treatment for recurrent endometrial carcinoma: a Gynecologic Oncology Group study,” American Journal of Clinical Oncology, vol. 25, no. 6, pp. 557–560, 2002. View at Publisher · View at Google Scholar · View at Scopus
  46. I. Noci, P. Borri, G. Bonfirraro et al., “Longstanding survival without cancer progression in a patient affected by endometrial carcinoma treated primarily with leuprolide,” British Journal of Cancer, vol. 85, no. 3, pp. 333–336, 2001. View at Publisher · View at Google Scholar · View at Scopus